These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 20668673)
1. Modelling cognitive decline in the Hypertension in the Very Elderly Trial [HYVET] and proposed risk tables for population use. Peters R; Beckett N; Beardmore R; Peña-Miller R; Rockwood K; Mitnitski A; Mt-Isa S; Bulpitt C PLoS One; 2010 Jul; 5(7):e11775. PubMed ID: 20668673 [TBL] [Abstract][Full Text] [Related]
2. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Peters R; Beckett N; Forette F; Tuomilehto J; Clarke R; Ritchie C; Waldman A; Walton I; Poulter R; Ma S; Comsa M; Burch L; Fletcher A; Bulpitt C; Lancet Neurol; 2008 Aug; 7(8):683-9. PubMed ID: 18614402 [TBL] [Abstract][Full Text] [Related]
3. A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG) : An ongoing randomised, double-blind, placebo-controlled trial. Peters R; Beckett N; Nunes M; Fletcher A; Forette F; Bulpitt C Drugs Aging; 2006; 23(1):83-92. PubMed ID: 16492072 [TBL] [Abstract][Full Text] [Related]
4. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Tzourio C; Anderson C; Chapman N; Woodward M; Neal B; MacMahon S; Chalmers J; Arch Intern Med; 2003 May; 163(9):1069-75. PubMed ID: 12742805 [TBL] [Abstract][Full Text] [Related]
5. Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. Peters R; Beckett N; Forette F; Tuomilehto J; Ritchie C; Walton I; Waldman A; Clarke R; Poulter R; Fletcher A; Bulpitt C Int Psychogeriatr; 2009 Apr; 21(2):359-68. PubMed ID: 19250558 [TBL] [Abstract][Full Text] [Related]
6. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. Warwick J; Falaschetti E; Rockwood K; Mitnitski A; Thijs L; Beckett N; Bulpitt C; Peters R BMC Med; 2015 Apr; 13():78. PubMed ID: 25880068 [TBL] [Abstract][Full Text] [Related]
7. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Bulpitt C; Fletcher A; Beckett N; Coope J; Gil-Extremera B; Forette F; Nachev C; Potter J; Sever P; Staessen J; Swift C; Tuomilehto J Drugs Aging; 2001; 18(3):151-64. PubMed ID: 11302283 [TBL] [Abstract][Full Text] [Related]
8. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. Beckett N; Peters R; Tuomilehto J; Swift C; Sever P; Potter J; McCormack T; Forette F; Gil-Extremera B; Dumitrascu D; Staessen JA; Thijs L; Fletcher A; Bulpitt C; BMJ; 2011 Jan; 344():d7541. PubMed ID: 22218098 [TBL] [Abstract][Full Text] [Related]
9. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial - HYVET. Peters R; Beckett N; Fagard R; Thijs L; Wang JG; Forette F; Pereira L; Fletcher A; Bulpitt C J Hypertens; 2013 Sep; 31(9):1868-75. PubMed ID: 23743809 [TBL] [Abstract][Full Text] [Related]
10. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Bulpitt CJ; Beckett N; Peters R; Staessen JA; Wang JG; Comsa M; Fagard RH; Dumitrascu D; Gergova V; Antikainen RL; Cheek E; Rajkumar C Hypertension; 2013 Jan; 61(1):89-94. PubMed ID: 23172934 [TBL] [Abstract][Full Text] [Related]
11. Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial. Peters R; Beckett N; Poulter R; Burch L; Narkiewicz K; Fagard R; Nitsch D; Wang N; Li M; Fletcher A; Bulpitt C Age Ageing; 2013 Mar; 42(2):253-8. PubMed ID: 22910302 [TBL] [Abstract][Full Text] [Related]
12. Older age should not be a barrier to the treatment of hypertension. Aronow WS Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):514-5. PubMed ID: 18607394 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. Chalmers J; Castaigne A; Morgan T; Chastang C J Hypertens; 2000 Mar; 18(3):327-37. PubMed ID: 10726720 [TBL] [Abstract][Full Text] [Related]
14. Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). Bulpitt CJ; Beckett NS; Peters R; Leonetti G; Gergova V; Fagard R; Burch LA; Banya W; Fletcher AE J Hum Hypertens; 2012 Mar; 26(3):157-63. PubMed ID: 21390056 [TBL] [Abstract][Full Text] [Related]
15. The Hypertension in the Very Elderly Trial - latest data. Mukhtar O; Jackson SH Br J Clin Pharmacol; 2013 Apr; 75(4):951-4. PubMed ID: 22897422 [TBL] [Abstract][Full Text] [Related]
16. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963 [TBL] [Abstract][Full Text] [Related]
17. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Skoog I; Lithell H; Hansson L; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A; Am J Hypertens; 2005 Aug; 18(8):1052-9. PubMed ID: 16109319 [TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET). Bulpitt CJ; Beckett NS; Peters R; Banya W; Liu L; Wang JG; Stoyanovsky V; Dumitrascu D; Nikitin Y; Staessen JA; Burch L; Fletcher AE Blood Press; 2009; 18(1-2):17-22. PubMed ID: 19353407 [TBL] [Abstract][Full Text] [Related]
19. Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. Gueyffier F; Subtil F; Bejan-Angoulvant T; Zerbib Y; Baguet JP; Boivin JM; Mercier A; Leftheriotis G; Gagnol JP; Fauvel JP; Giraud C; Bricca G; Maucort-Boulch D; Erpeldinger S; J Hum Hypertens; 2015 Jan; 29(1):22-7. PubMed ID: 24739801 [TBL] [Abstract][Full Text] [Related]
20. Combination perindopril/indapamide for the treatment of hypertension: a review. de Leeuw PW Expert Opin Pharmacother; 2011 Aug; 12(11):1827-33. PubMed ID: 21651456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]